These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7258385)

  • 1. Physostigmine and lithium response in the schizophrenias.
    Edelstein P; Schultz JR; Hirschowitz J; Kanter DR; Garver DL
    Am J Psychiatry; 1981 Aug; 138(8):1078-81. PubMed ID: 7258385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to lithium in patients with psychoses.
    Schexnayder LW; Hirschowitz J; Sautter FJ; Garver DL
    Am J Psychiatry; 1995 Oct; 152(10):1511-3. PubMed ID: 7573592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
    van Kammen DP; Bunney WE; Docherty JP; Marder SR; Ebert MH; Rosenblatt JE; Rayner JN
    Am J Psychiatry; 1982 Aug; 139(8):991-7. PubMed ID: 7091448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.
    Terao T; Oga T; Nozaki S; Ohta A; Ohtsubo Y; Yamamoto S; Zamami M; Okada M
    Acta Psychiatr Scand; 1995 Sep; 92(3):220-4. PubMed ID: 7484202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic effects of lithium in schizophrenia.
    Alexander PE; van Kammen DP; Bunney WE
    Am J Psychiatry; 1979 Mar; 136(3):283-7. PubMed ID: 369396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenia and treatment with lithium salts. Current data from the literature].
    Matot JP; Olié JP; Lôo H
    Encephale; 1983; 9(1):49-57. PubMed ID: 6872934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithium response in good prognosis schizophrenia.
    Hirschowitz J; Casper R; Garver DL; Chang S
    Am J Psychiatry; 1980 Aug; 137(8):916-20. PubMed ID: 7416291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients.
    van Kammen DP; Docherty JP; Marder SR; Bunney WE
    Psychiatry Res; 1981 Jun; 4(3):313-25. PubMed ID: 6115437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosis, lithium-induced antipsychotic response, and seasonality.
    Garver DL; Hutchinson LJ
    Psychiatry Res; 1988 Dec; 26(3):279-86. PubMed ID: 3146760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse in patients with shifting RDC diagnoses treated with lithium alone.
    Glazer WM; Sheard MH
    J Clin Psychiatry; 1982 Apr; 43(4):134-6. PubMed ID: 7068543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium and chlorpromazine in psychotic inpatients.
    Braden W; Fink EB; Qualls CB; Ho CK; Samuels WO
    Psychiatry Res; 1982 Aug; 7(1):69-81. PubMed ID: 6813888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.
    Davis KL; Berger PA
    Biol Psychiatry; 1978 Feb; 13(1):23-49. PubMed ID: 146524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)].
    Modestin J; Schwartz RB; Hunger J
    Pharmakopsychiatr Neuropsychopharmakol; 1973 Nov; 6(6):300-4. PubMed ID: 4603643
    [No Abstract]   [Full Text] [Related]  

  • 16. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lithium therapy on core psychotic symptoms of schizophrenia.
    Zemlan FP; Hirschowitz J; Sautter FJ; Garver DL
    Br J Psychiatry; 1984 Jan; 144():64-9. PubMed ID: 6419805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium carbonate in chronic schizophrenia--a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients.
    Collins PJ; Larkin EP; Shubsachs AP
    Acta Psychiatr Scand; 1991 Aug; 84(2):150-4. PubMed ID: 1683094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.